Efficacy and safety of mufemilast in patients with Behçet’s syndrome: a phase 2 randomised clinical trial
Annals of the Rheumatic Diseases · 2026
DOI: 10.1016/j.ard.2026.01.014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Tian Liu und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Peking Universi…. Hauptthemen laut MEDLINE: Behcet Syndrome, Phosphodiesterase 4 Inhibitors, Oral Ulcer, Benzamides. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVES: This study aimed to evaluate the efficacy and safety of mufemilast, a novel small-molecule selective phosphodiesterase 4 (PDE4) inhibitor, in patients with Behçet's syndrome (BS). METHODS: Patients diagnosed with BS according to the International Diagnostic (Classification) Criteria for Behçet's Disease 2013 and with active oral ulcers were eligible. Patients were randomly assigned to mufemilast (45 mg or 60 mg) or placebo, administered orally twice daily for 12 weeks. The primary endpoint was the area under the curve (AUC) for the number of oral ulcers from baseline to week 12. Safety was measured in all patients who received at least 1 dose of the study drug (ClinicalTrials: NCT04609397). RESULTS: for oral ulcers between the 45 mg and 60 mg groups and the placebo was -104.8 (95% CI, -156.3 to -53.2; P < .001) and -142.5 (95% CI, -192.4 to -92.7; P < .001), respectively. The visual analogue pain scores and time to ulcer-free remission were significantly improved with mufemilast (P < .001). PDE4-related side effects were transient and resolved spontaneously, and discontinuation rates were low (7% for 45 mg, 7% for 60 mg, and 3% for placebo). No serious adverse events were reported related to the drug. CONCLUSIONS: Among patients with oral ulcers associated with BS, mufemilast significantly reduced the number of oral ulcers, improved pain scores, and induced significantly more ulcer-free remissions compared with placebo, with an acceptable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Peking University People's Hospital, Beijing, China.
- Peking Union Medical College Hospital, Beijing, China.
- Tongji Hospital Affiliated to Tongji University, Shanghai, China.
- The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
- The First Affiliated Hospital of Xiamen University, Fujian, China.
- The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China.
Zitieren
APA
Liu, T., Li, C., Zheng, W., Tang, J., Chen, D., Peng, Y., Yin, S., Zhou, D., Zhang, Z., Huang, C., Dai, L., Wei, X., Lin, J., Yu, Y., Wu, L., Zhang, Z., Liu, S., Li, X., Jiang, L., …, & Li, Z. (2026). Efficacy and safety of mufemilast in patients with Behçet’s syndrome: a phase 2 randomised clinical trial. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.01.014
Vancouver
Liu T, Li C, Zheng W, Tang J, Chen D, Peng Y, et al. Efficacy and safety of mufemilast in patients with Behçet’s syndrome: a phase 2 randomised clinical trial. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.01.014
BibTeX
@article{Liu2026,
author = {Liu, Tian and Li, Chun and Zheng, Wenjie and Tang, Jianping and Chen, Dan and Peng, Yun and Yin, Songlou and Zhou, Dongmei and Zhang, Zhuoli and Huang, Cibo and Dai, Lie and Wei, Xiuning and Lin, Jin and Yu, Ye and Wu, Lijun and Zhang, Zhenchun and Liu, Shengyun and Li, Xiaomei and Jiang, Lindi and Wu, Jian and Zhao, Yi and Chen, Lin and Meng, Tianli and Wu, Ling and Wang, Yongfu and Wan, Weiguo and Kong, Ning and Ke, Yao and Bi, Liqi and Li, Yasong and Dang, Wantai and Zhang, Hesheng and Jones, Richard and Li, Zhanguo},
title = {Efficacy and safety of mufemilast in patients with Behçet’s syndrome: a phase 2 randomised clinical trial},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
doi = {10.1016/j.ard.2026.01.014}
}
EUVIMED